JP2023553216A5 - - Google Patents
Info
- Publication number
- JP2023553216A5 JP2023553216A5 JP2023559969A JP2023559969A JP2023553216A5 JP 2023553216 A5 JP2023553216 A5 JP 2023553216A5 JP 2023559969 A JP2023559969 A JP 2023559969A JP 2023559969 A JP2023559969 A JP 2023559969A JP 2023553216 A5 JP2023553216 A5 JP 2023553216A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- polypeptide
- composition according
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123281P | 2020-12-09 | 2020-12-09 | |
| US63/123,281 | 2020-12-09 | ||
| PCT/US2021/062484 WO2022125711A1 (en) | 2020-12-09 | 2021-12-08 | Targeted cytokine construct for engineered cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553216A JP2023553216A (ja) | 2023-12-20 |
| JP2023553216A5 true JP2023553216A5 (enExample) | 2024-12-10 |
Family
ID=81972793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559969A Pending JP2023553216A (ja) | 2020-12-09 | 2021-12-08 | 遺伝子操作細胞療法のための標的化サイトカイン構築物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043490A1 (enExample) |
| EP (1) | EP4259213A4 (enExample) |
| JP (1) | JP2023553216A (enExample) |
| KR (1) | KR20230129983A (enExample) |
| CN (1) | CN116829194A (enExample) |
| AU (1) | AU2021397271A1 (enExample) |
| CA (1) | CA3201573A1 (enExample) |
| WO (1) | WO2022125711A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102760578B1 (ko) | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス，インク． | タンパク質複合体の組成物及びその使用方法 |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
| GB2638094B (en) | 2021-05-19 | 2026-03-04 | Asher Biotherapeutics Inc | IL-21 Polypeptides And Targeted Constructs |
| US20260022190A1 (en) * | 2022-07-08 | 2026-01-22 | Shenghe (China) Biopharmaceutical Co., Ltd. | Heterodimeric fusion protein and use thereof |
| EP4562131A2 (en) * | 2022-07-25 | 2025-06-04 | Memorial Sloan Kettering Cancer Center | Manufacturing processes for adoptive cell therapies |
| WO2025059162A1 (en) * | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| CN117904196B (zh) * | 2024-01-05 | 2024-07-12 | 安徽大学 | 一种非小细胞肺癌组蛋白h1.4赖氨酸乙酰化点突变细胞模型的构建及其应用 |
| CN120230182B (zh) * | 2025-05-29 | 2025-08-22 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽及其核素标记物与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3102594A1 (en) * | 2014-02-06 | 2016-12-14 | F. Hoffmann-La Roche AG | Interleukine 10 immunoconjugates |
| CN111094330A (zh) * | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
| TWI901940B (zh) * | 2017-08-03 | 2025-10-21 | 美商安進公司 | 介白素-21突變蛋白及治療方法 |
| WO2019166946A1 (en) * | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
| MX2021008147A (es) * | 2019-01-07 | 2021-08-11 | Inhibrx Inc | Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos. |
-
2021
- 2021-12-08 AU AU2021397271A patent/AU2021397271A1/en active Pending
- 2021-12-08 CA CA3201573A patent/CA3201573A1/en active Pending
- 2021-12-08 KR KR1020237022145A patent/KR20230129983A/ko active Pending
- 2021-12-08 EP EP21904356.9A patent/EP4259213A4/en active Pending
- 2021-12-08 US US18/256,512 patent/US20240043490A1/en active Pending
- 2021-12-08 CN CN202180093384.4A patent/CN116829194A/zh active Pending
- 2021-12-08 JP JP2023559969A patent/JP2023553216A/ja active Pending
- 2021-12-08 WO PCT/US2021/062484 patent/WO2022125711A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023233125B2 (en) | Anti-KRAS-G12D T cell receptors | |
| AU2018342245B2 (en) | Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation | |
| Ghia et al. | Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 | |
| TWI908730B (zh) | 識別p53中之r175h或y220c突變之t細胞受體 | |
| TWI713798B (zh) | 增加介白素－２（ｉｌ－２）分泌量之方法和源自該方法之蛋白類 | |
| JP2021502114A (ja) | 改変された免疫細胞およびその使用 | |
| US10919950B2 (en) | Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment | |
| Mrózek et al. | Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells | |
| KR20120093002A (ko) | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 | |
| JP2025163198A (ja) | キメラサイトカイン受容体 | |
| JP2022520777A (ja) | ｉｎ ｖｉｖｏでの免疫細胞の増殖をブースト可能なアジュバント | |
| CN114901684A (zh) | 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子 | |
| TW201835100A (zh) | 新穎ｔ細胞受體 | |
| US20250129169A1 (en) | Surrogate cytokine polypeptides | |
| Liu et al. | Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome | |
| Chilakapati et al. | Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma | |
| CN119371485B (zh) | 源自长链非编码rna slc12a5-as1的hla-a*11:01肾细胞癌肿瘤抗原短肽及其应用 | |
| CN119371486B (zh) | 源自长链非编码rna linc02717的hla-a*11:01肾细胞癌肿瘤抗原短肽 | |
| Di Roberto et al. | speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing | |
| CN119751558B (zh) | 源自长链非编码rna ensg00000286147的hla-a*24:02肾细胞癌肿瘤抗原短肽 | |
| WO2019122875A1 (en) | Chimeric antigen receptor | |
| CN119390792B (zh) | 源自人逆转录病毒herv3895基因的hla-a*2402肾细胞癌肿瘤抗原短肽 | |
| CN113785201B (zh) | 用于检测镍纹蛋白-β活性的方法 | |
| WO2024213695A1 (en) | Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27 | |
| Bradl et al. | The pre‐B cell receptor and its ligands–it takes two to tango |